192 related articles for article (PubMed ID: 1361822)
21. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
22. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
23. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
[TBL] [Abstract][Full Text] [Related]
24. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
Dong J; Wang H; Wang M
J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
[TBL] [Abstract][Full Text] [Related]
25. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
[TBL] [Abstract][Full Text] [Related]
26. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J
Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365
[TBL] [Abstract][Full Text] [Related]
27. Differences in corrective mode for divalent ions and parathyroid hormone between standard- and low-calcium dialysate in patients on continuous ambulatory peritoneal dialysis--result of a nationwide survey in Japan.
Yamamoto H; Kasai K; Hamada C; Hasegawa H; Higuchi C; Hiramatsu M; Hosoya T; Itami N; Kawanishi H; Kubota M; Masakane I; Minakuchi J; Mitarai T; Nakao T; Suzuki H; Tomo T; Kawaguchi Y;
Perit Dial Int; 2008 Jun; 28 Suppl 3():S128-30. PubMed ID: 18552242
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
[TBL] [Abstract][Full Text] [Related]
29. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
[TBL] [Abstract][Full Text] [Related]
30. Calcium mass transfer in peritoneal dialysis patients using 2.5 mEq/l calcium dialysate.
Piraino B; Bernardini J; Holley J; Johnston JR; Perlmutter JA; Martis L
Clin Nephrol; 1992 Jan; 37(1):48-51. PubMed ID: 1541065
[TBL] [Abstract][Full Text] [Related]
31. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
32. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
[TBL] [Abstract][Full Text] [Related]
33. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age.
Heaf JG; Løkkegård H
J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872
[TBL] [Abstract][Full Text] [Related]
34. Effects of lowering dialysate calcium concentration on mineral metabolism and hemodynamic parameters in hemodialysis patients.
Alayoud A; El Kabbaj D; Benyahia M; Asseraji M; Zemraoui N
Iran J Kidney Dis; 2015 Mar; 9(2):132-7. PubMed ID: 25851292
[TBL] [Abstract][Full Text] [Related]
35. [The impact of low calcium dialysate (1.25 mmol/l; LCD) on bone metabolism in CAPD patients].
Terawaki H; Kasai K; Kawaguchi Y; Kobayashi H; Hirano K; Ohtsuka Y; Hosoya T
Nihon Jinzo Gakkai Shi; 1998 May; 40(4):252-7. PubMed ID: 9654908
[TBL] [Abstract][Full Text] [Related]
36. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize?
Bro S; Brandi L; Daugaard H; Olgaard K
Perit Dial Int; 1997; 17(6):554-9. PubMed ID: 9655154
[TBL] [Abstract][Full Text] [Related]
37. Low-calcium dialysate as a risk factor for decline in bone mineral density in peritoneal dialysis patients.
Kang SH; Cho KH; Park JW; Yoon KW; Do JY
Scand J Urol Nephrol; 2012 Dec; 46(6):454-60. PubMed ID: 22938029
[TBL] [Abstract][Full Text] [Related]
38. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
Zellweger U; Zaugg PY; Dambacher M; Binswanger U; Gautschi K; Hany A
Dtsch Med Wochenschr; 1989 Apr; 114(17):659-64. PubMed ID: 2707134
[TBL] [Abstract][Full Text] [Related]
39. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
40. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
